NASDAQ · Biotechnology

Morphic Holding, Inc. (MORF) Stock

$56.99 +0.04% NASDAQ: MORF Healthcare

Morphic Holding, Inc. is a biopharmaceutical company dedicated to the discovery and advancement of oral, small-molecule integrin-based therapies.

Valuation

MetricValue
Price$56.99
Market Cap$2.86B
P/E Ratio-15.87
P/B Ratio3.47
P/S Ratio5493.87
EPS (TTM)$-3.59
52-Week High$57.00
52-Week Low$19.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-29.08%
ROA-21.05%
ROCE-25.61%
Gross Margin-109.40%
Operating Margin-17900.00%
Net Margin-15200.00%
Debt/Equity0.00
Current Ratio28.94

Annual Financials (USD)

Metric20192020202120222023
Revenue$17.0M$45.0M$20.0M$71.0M$1.0M
Operating Profit$-47.0M$-47.0M$-96.0M$-63.0M$-179.0M
Net Profit$-43.0M$-45.0M$-94.0M$-59.0M$-152.0M
EPS$-1.44$-1.47$-2.63$-1.55$-3.59
Op Margin-276.8%-105.0%-484.0%-89.5%-34296.7%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$247.0M$242.0M$426.0M$369.0M$723.0M
Total Liabilities$107.0M$97.0M$90.0M$19.0M$25.0M
Cash$102.0M$102.0M$408.0M$59.0M$59.0M
Borrowings$0$0$5.0M$4.0M$2.0M

Latest News

Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy Business Wire · Jul 16, 2026 India ask its seafarers not to take Hormuz voyages Reuters · Jul 16, 2026 AI chatbots are at risk of spreading government restrictions on online speech, a new study says Associated Press · Jul 16, 2026 Stock market today: Dow, S&P 500, Nasdaq futures mixed ahead of Netflix earnings Yahoo Finance · Jul 16, 2026 Wells Fargo Adjusts Price Target on Cintas to $250 From $245, Maintains Overweight Rating MT Newswires · Jul 16, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-42.0M$-46.0M$-83.0M$-101.0M$-112.0M
Investing Cash Flow$-138.0M$8.0M$-114.0M$-57.0M$-343.0M
Financing Cash Flow$93.0M$1.0M$11.0M$6.0M$10.0M
Net Cash Flow$-84.0M$0$70.0M$-112.0M$-1.0M
Free Cash Flow$-44.0M$-47.0M$-84.0M$-101.0M$-114.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.41
EV / EBITDA-15.80
FCF Yield-3.97%
Quick Ratio28.94
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BLUBELLUS Health Inc. $14.75 +0.03% -22.34 $1.87B 0.00%
CALTCalliditas Therapeutics AB (publ) $40.00 -0.10% -22.08 $2.15B 0.00%
DICEDICE Therapeutics, Inc. $47.55 +0.06% -22.97 $2.27B 0.00%
FUSNFusion Pharmaceuticals Inc. $21.55 +0.14% -14.86 $1.83B 0.00%
KDNYChinook Therapeutics, Inc. $40.39 +0.22% -14.07 $2.71B 0.00%

About Morphic Holding, Inc.

Morphic Holding, Inc. is a biopharmaceutical company dedicated to the discovery and advancement of oral, small-molecule integrin-based therapies. These treatments are designed to address a broad spectrum of conditions, including autoimmune, cardiovascular, and metabolic diseases, as well as various forms of fibrosis and cancer. The company's principal therapeutic candidates include MORF-057, an a4ß7-specific integrin inhibitor targeting inflammation, currently undergoing Phase 1 clinical trials for inflammatory bowel disease and in preclinical development for idiopathic pulmonary fibrosis and other fibrotic ailments. Additionally, Morphic is progressing avß6 for fibrotic disorders and avß8 for solid tumor applications, alongside a pipeline of other innovative products. Morphic has established strategic collaborations, including a research partnership with Engitix Ltd concerning integrin technology for fibrostenotic IBD, an agreement with Schrödinger, LLC focused on integrin targets, and a licensing arrangement with Children's Medical Center Corporation for the global development and commercialization of products for human and veterinary therapeutic or diagnostic uses. Further collaborative efforts involve AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. for the discovery and development of integrin-based therapeutics. Established in 2014, Morphic Holding, Inc. operates from its headquarters in Waltham, Massachusetts.

Morphic Holding, Inc. is headquartered in US.

Morphic Holding, Inc. (MORF) stock trades at $56.99 with a market capitalization of $2.86B. The stock is valued at a price-to-earnings (P/E) ratio of -15.87, price-to-book of 3.47, price-to-sales of 5493.87. Over the past 52 weeks the stock has ranged between $19.35 and $57.00, and currently trades at its 52-week high.

On profitability, Morphic Holding, Inc. generates a return on equity (ROE) of -29.08%, return on capital employed of -25.61%, an operating margin of -17900.00%, a net profit margin of -15200.00%.

Official website: www.morphictx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides